Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.62 |
| ▸ | NAAA | Q02083 | 1/20 | 0.59 |
| ▸ | FAAH | O00519 | 5/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.51 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1146790 | 0.93 | CASP2 (0.71) | CASP2NAAAFAAHEPHX2DNM1 | |
| SCHEMBL9502450 | 0.93 | CASP2 (0.71) | CASP2NAAAFAAHEPHX2DNM1 | |
| SCHEMBL9518701 | 0.93 | CASP2 (0.71) | CASP2NAAAFAAHEPHX2DNM1 | |
| SCHEMBL9518772 | 0.91 | CASP2 (0.68) | CASP2NAAAFAAHEPHX2DNM1 | |
| SCHEMBL12300414 | 0.90 | CASP2 (0.54) | CASP2NAAAFAAHEPHX2DNM1 | |
| SCHEMBL2616429 | 0.90 | CASP2 (0.67) | CASP2NAAAFAAHEPHX2DNM1 | |
| SCHEMBL25922800 | 0.88 | CASP2 (0.65) | CASP2NAAAFAAHEPHX2DNM1 | |
| SCHEMBL23394708 | 0.87 | CASP2 (0.62) | CASP2NAAAFAAHEPHX2DNM1 | |
| SCHEMBL14878514 | 0.87 | LMNA (0.46) | CASP2NAAAFAAHEPHX2 | |
| SCHEMBL21779474 | 0.86 | CASP2 (0.61) | CASP2NAAAFAAHEPHX2SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160376591-A1 | iRNA AGENTS WITH BIOCLEAVABLE TETHERS | BANK OF AMERICA, N.A. | 2016-12-29 | — | — | US | disclosed |
| US-9476045-B2 | iRNA agents with biocleavable tethers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-9476045-B2 | iRNA agents with biocleavable tethers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-20150073133-A1 | iRNA AGENTS WITH BIOCLEAVABLE TETHERS | BANK OF AMERICA, N.A. | 2015-03-12 | — | — | US | disclosed |
| US-20150073133-A1 | iRNA AGENTS WITH BIOCLEAVABLE TETHERS | BANK OF AMERICA, N.A. | 2015-03-12 | — | — | US | disclosed |
| US-8865677-B2 | iRNA agents with biocleavable tethers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20130281685-A1 | iRNA AGENTS WITH BIOCLEAVABLE TETHERS | BANK OF AMERICA, N.A. | 2013-10-24 | — | — | US | disclosed |
| US-8426377-B2 | iRNA agents with biocleavable tethers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8349308-B2 | Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof | MERSANA THERAPEUTICS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20110243880-A1 | MODIFIED POLYMERS FOR DELIVERY OF POLYNUCLEOTIDES, METHOD OF MANUFACTURE, AND METHODS OF USE THEREOF | MERSANA THERAPEUTICS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-8017762-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100267941-A1 | IRNA AGENTS WITH BIOCLEAVABLE TETHERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-7723509-B2 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to target tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; biodrugs | ALNYLAM PHARMACEUTICALS (US) | 2010-05-25 | — | — | US | disclosed |
| US-20100076056-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110243880-A1 | MODIFIED POLYMERS FOR DELIVERY OF POLYNUCLEOTIDES, METHOD OF MANUFACTURE, AND METHODS OF USE THEREOF | ZYX, NSUN3, NSUN2 | CASP2 4271/4885NAAA 2936/4885FAAH 4751/4885 |
| US-20100076056-A1 | MODIFIED iRNA AGENTS | LDLR, RNASE1, SARNP | CASP2 913/4885NAAA 2470/4885FAAH 4243/4885 |
| US-20100267941-A1 | IRNA AGENTS WITH BIOCLEAVABLE TETHERS | DCLRE1A, PARP1, LIG1 | CASP2 529/4885NAAA 1385/4885FAAH 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.